These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 6441709)

  • 41. In vitro susceptibility of clinically important bacteria to amikacin: correlation of results of broth dilution and disk sensitivity tests and effect of medium composition.
    Linzenmeier G; Naumann P; Neussel H; Rosin H
    J Infect Dis; 1976 Nov; 134 SUPPL():S262-70. PubMed ID: 825584
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cefsulodin: antibacterial activity and tentative interpretive zone standards for the disk susceptibility test.
    Barry AL; Jones RN; Thornsberry C
    Antimicrob Agents Chemother; 1981 Oct; 20(4):525-9. PubMed ID: 6211134
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Susceptibility of recently isolated bacteria to amikacin in vitro: comparisons with four other aminoglycoside antibiotics.
    Finland M; Garner C; Wilcox C; Sabath LD
    J Infect Dis; 1976 Nov; 134 SUPPL():S297-307. PubMed ID: 825588
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CI-934, a new difluoroquinolone: in vitro antibacterial activity and proposed disk diffusion test interpretive criteria.
    Fuchs PC; Barry AL; Jones RN; Thornsberry C; Ayers LW; Gavan TL; Gerlach EH
    Diagn Microbiol Infect Dis; 1987 Mar; 6(3):185-92. PubMed ID: 3471371
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ["In vitro" determination of bacterial sensitivity to tobramycin (author's transl)].
    Talon D; Michel-Briand Y
    Pathol Biol (Paris); 1976 Jan; 24(1):25-30. PubMed ID: 817253
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antimicrobial susceptibility tests with cefotaxime and correlation with clinical bacteriologic response.
    Thornsberry C; Jones RN; Barry AL; Fuchs PC
    Rev Infect Dis; 1982; 4 Suppl():S316-24. PubMed ID: 6294780
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Suceptibility of aminoglycoside-resistant gram-negative bacilli to amikacin: delineation of individual resistance patterns.
    Acar JF; Witchitz JL; Goldstein F; Talbot JN; Le Goffic F
    J Infect Dis; 1976 Nov; 134 SUPPL():S280-5. PubMed ID: 825587
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia.
    Sader HS; Rhomberg PR; Farrell DJ; Jones RN
    Antimicrob Agents Chemother; 2015; 59(6):3263-70. PubMed ID: 25801559
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative in vitro activity of Ro 09-1428, a novel cephalosporin with a catechol moiety.
    Qadri SM; Ayub A; Ueno Y; Saldin H
    Clin Ther; 1992; 14(4):562-9. PubMed ID: 1525790
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Control of emergence of multi-resistant gram-negative bacilli by exclusive use of amikacin.
    Ruiz-Palacios GM; Ponce de Leon S; Sifuentes J; Ponce de Leon S; Calva JJ; Huazano F; Ontiveros C; Ojeda F; Bobadilla M
    Am J Med; 1986 Jun; 80(6B):71-5. PubMed ID: 3089006
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro activity of amikacin and ten other aminoglycoside antibiotics against gentamicin-resistant bacterial strains.
    Reyonolds AV; Hamilton-Miller JM; Brumfitt W
    J Infect Dis; 1976 Nov; 134 SUPPL():S291-6. PubMed ID: 62815
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Comparative study of the sensitivity of Enterobacteriaceae and Pseudomonas aeruginosa with 4 aminoglycosides].
    Turgeon P; Lamothe F; Vincelette J; Gaudreau C; Bourgault AM; Turgeon F
    Union Med Can; 1984 Jun; 113(6):522-4. PubMed ID: 6435299
    [No Abstract]   [Full Text] [Related]  

  • 53. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions.
    Giamarellou H
    Am J Med; 1986 Jun; 80(6B):126-37. PubMed ID: 3088998
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-enteric gram-negative bacilli: occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes.
    Jones RN; Pfaller MA; Marshall SA; Hollis RJ; Wilke WW
    Diagn Microbiol Infect Dis; 1997 Nov; 29(3):187-92. PubMed ID: 9401811
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antimicrobial activity of netilmicin in comparison with gentamicin, sisomicin, tobramycin, and amikacin and their resistance patterns.
    Braveny I; Voeckl J; Machka K
    Arzneimittelforschung; 1980; 30(3):491-5. PubMed ID: 7387761
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interpretive standards for disk susceptibility tests with Sch 21420 and amikacin.
    Barry AL; Thornsberry C; Jones RN; Gerlach EH
    Antimicrob Agents Chemother; 1980 Oct; 18(4):616-21. PubMed ID: 7447420
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gentamicin and tobramycin--an in vitro comparison using 1400 clinical isolates.
    Forgan-Smith WR; Andrew JH; McSweeney RJ
    Pathology; 1976 Jul; 8(3):195-9. PubMed ID: 826868
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Surveillance of aminoglycoside resistance. European data.
    Van Landuyt HW; Boelaert J; Glibert B; Gordts B; Verbruggen AM
    Am J Med; 1986 Jun; 80(6B):76-81. PubMed ID: 3089007
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interpretive criteria for temocillin disk diffusion susceptibility testing.
    Fuchs PC; Barry AL; Thornsberry C; Jones RN
    Eur J Clin Microbiol; 1985 Feb; 4(1):30-3. PubMed ID: 3872793
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Susceptibility testing with fosfomycin in an agar diffusion test on Mueller-Hinton agar].
    Grimm H; Haag R
    Immun Infekt; 1982 Jul; 10(4):159-63. PubMed ID: 6813250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.